Funding Innovation in Biotech: A Conversation with Congress and Industry Analysts

By: Kyle Brandon

It can take 14 years and up to $2 billion to bring a medicine to market. How does the biotech industry fund extraordinary innovations? Venture capital investments and capital markets (i.e. IPOs and secondary offerings).

Biotechnology is an evolving industry that improves lives through the development of treatments and cures for some of today’s most pressing medical challenges, while also fueling innovation, economic growth and job creation across America. At a roundtable discussion on Capitol Hill, Members of Congress and industry analysts from RBC Capital Markets and Jefferies discuss the state of the biotech industry today and the role of America’s capital markets in funding new

innovations.

Read More:

Biotech Hill Roundtable: A Conversation with Congress and the Financial Services Industry  

Biotechnology Roundtable Press Release

Biotechnology Fact Sheet: Funding Innovation in Biotechnology

Project Invested: How biotech investment is revolutionizing health care treatments

Project Invested: What You Need to Know About the Biotech Revolution in Agriculture

SIFMA would like to extend a special thank you to our roundtable participants who provided their expertise and delivered insights into this important segment: Representative French Hill (R-AR); Representative Scott Peters (D-CA); Representative Leonard Lance (R-NJ); Michael Yee, Managing Director, RBC Capital Markets; and Brian Abrahams, M.D., Managing Director, Jefferies.